Mayo Clinic Laboratories’ definitive testing approach utilizes mass spectrometry technology to accurately identify parent drugs and metabolites of substances, which, because of complex metabolic processes, similar chemical structures, and pharmaceutical impurities, could interfere with the results of immunoassay screening. Our fast and cost-effective definitive tests are available in a variety of configurations, including individually, for each drug of abuse class.
Our approach gives providers the flexibility to perform immunoassays locally while enabling confidence through confirmatory testing. Quantitative results from individual drug confirmations can be useful for managing complex cases, including instances where testing results are questioned or denied. Test reports identify specific drug findings and their concentrations.
Confirmatory testing menu
Opiates
Semi-synthetics
Synthetics
Alcohol
Barbiturates
Benzodiazepines
Amphetamine-type stimulants
Cocaine
Methylphenidate (Ritalin)
Marijuana (THC)
Phencyclidine (PCP)
Highlights
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and characterize patients’ marijuana use.